Related Experiment Videos
Immunotherapy for Alzheimer's disease: will vaccination work?
Jean-Cosme Dodart1, Kelly R Bales, Steven M Paul
1Lilly Research Laboratories, Eli Lilly and Company, Neuroscience Discovery Research, Indianapolis, IN 46285, USA.
Trends in Molecular Medicine
|March 27, 2003
Summary
Immunotherapy targeting beta-amyloid may treat Alzheimer's disease (AD), but safety concerns exist. Careful antigen selection is crucial for effective and safe AD immunotherapy development.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Beta-amyloid peptide (Abeta) accumulation is a key pathological hallmark of AD.
- Immunotherapy targeting Abeta has shown promise in preclinical models of AD.
Purpose of the Study:
- To evaluate the potential of active or passive immunization against Abeta for AD prevention and treatment.
- To assess the efficacy and safety of Abeta-targeted immunotherapy.
Main Methods:
- Review of preclinical studies in transgenic mouse models of AD.
- Analysis of clinical trial data for Abeta-based vaccines.
- Consideration of recent reports on antigen and antibody selection for immunotherapy.
Main Results:
- Preclinical studies demonstrated Abeta reduction and improved memory in mouse models.
- A clinical trial using active immunization was halted due to meningoencephalitis, a serious adverse event.
- Recent findings emphasize the need for careful selection of antigens and antibodies to optimize efficacy and safety.
Conclusions:
- Abeta immunotherapy shows potential for Alzheimer's disease treatment, but safety concerns must be addressed.
- Careful selection of antigens and antibodies is critical for developing safe and effective AD immunotherapies.
- Immunotherapy for AD should not be abandoned but pursued with cautious optimization.